Savara (SVRA) to Release Earnings on Tuesday

Savara (NASDAQ:SVRA) is expected to post its Q4 2025 results before the market opens on Tuesday, March 31st. Analysts expect the company to announce earnings of ($0.12) per share for the quarter. Individuals are encouraged to explore the company’s upcoming Q4 2025 earning overview page for the latest details on the call scheduled for Friday, March 13, 2026 at 7:00 AM ET.

Savara (NASDAQ:SVRA) last posted its earnings results on Friday, March 13th. The company reported ($0.13) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.12) by ($0.01). On average, analysts expect Savara to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Savara Stock Up 2.4%

Shares of Savara stock opened at $5.08 on Tuesday. Savara has a 1 year low of $1.89 and a 1 year high of $7.01. The company has a debt-to-equity ratio of 0.15, a current ratio of 11.85 and a quick ratio of 11.85. The company has a market capitalization of $1.04 billion, a P/E ratio of -9.58 and a beta of 0.31. The business has a 50-day moving average of $5.59 and a two-hundred day moving average of $5.04.

Wall Street Analyst Weigh In

A number of research firms recently issued reports on SVRA. Weiss Ratings reissued a “sell (d-)” rating on shares of Savara in a research note on Thursday, January 22nd. William Blair set a $10.00 price target on shares of Savara in a research note on Monday, March 16th. Wells Fargo & Company increased their price objective on shares of Savara from $7.00 to $9.00 and gave the stock an “overweight” rating in a research report on Thursday, December 18th. HC Wainwright restated a “buy” rating on shares of Savara in a report on Monday, March 16th. Finally, Guggenheim reaffirmed a “buy” rating on shares of Savara in a research report on Tuesday, December 23rd. One investment analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $9.00.

Institutional Inflows and Outflows

Hedge funds have recently bought and sold shares of the stock. Rhumbline Advisers raised its stake in shares of Savara by 10.8% during the 2nd quarter. Rhumbline Advisers now owns 170,176 shares of the company’s stock worth $388,000 after purchasing an additional 16,634 shares in the last quarter. Prudential Financial Inc. bought a new position in shares of Savara in the second quarter valued at $30,000. XTX Topco Ltd bought a new position in shares of Savara in the second quarter valued at $201,000. Invesco Ltd. increased its holdings in Savara by 35.4% during the second quarter. Invesco Ltd. now owns 120,891 shares of the company’s stock worth $276,000 after buying an additional 31,633 shares during the last quarter. Finally, The Manufacturers Life Insurance Company increased its holdings in Savara by 14.2% during the second quarter. The Manufacturers Life Insurance Company now owns 51,930 shares of the company’s stock worth $118,000 after buying an additional 6,449 shares during the last quarter. 87.93% of the stock is currently owned by institutional investors.

Savara Company Profile

Savara Inc (NASDAQ:SVRA) is a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for rare respiratory diseases. The company specializes in in-licensing, advancing and potentially bringing to market novel treatments that address severe pulmonary conditions with high unmet medical need.

The company’s lead candidate, Molgradex (recombinant human granulocyte-macrophage colony-stimulating factor, or GM-CSF), is under regulatory review for the treatment of autoimmune pulmonary alveolar proteinosis (PAP), a rare lung disease characterized by the accumulation of surfactant.